Logo

American Heart Association

  22
  0


Final ID: MP1979

Impact of β-Blocker Nebivolol versus Bisoprolol Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction (

Abstract Body (Do not enter title and authors here): Background: The comparative long-term outcomes of Nebivolol and Bisoprolol in ST-segment elevation myocardial infarction (STEMI) patients with reduced left ventricular ejection fraction (LVEF <40%) treated with drug-eluting stents (DESs) are not well understood. This study evaluated the efficacy and safety of these β-blockers in this population.
Methods: We analyzed data from the Korea Acute Myocardial Infarction Registry (KAMIR) involving STEMI patients with reduced LVEF treated with DESs. Patients were grouped based on Nebivolol or Bisoprolol prescription at discharge and followed for up to 3 years. The primary endpoint was all-cause death, while the secondary endpoint was major adverse cardiac events (MACE), defined as a composite of all-cause death, myocardial infarction (MI), and revascularization. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline confounders.
Results: After IPTW adjustment, baseline characteristics were well balanced between the Nebivolol group (n=654) and the Bisoprolol group (n=663). At 1 year, the incidence of total death was similar between the two groups (3.2% vs. 4.4%, HR: 0.724, 95% CI: 0.408–1.283, P=0.313), whereas the incidence of MACE was significantly lower in the Nebivolol group (5.2% vs. 10.0%, HR: 0.495, 95% CI: 0.322–0.760, P=0.001). Over the 3-year follow-up, the incidence of total death (5.5% vs. 7.1%, HR: 0.762, 95% CI: 0.486–1.193, P=0.257) remained comparable, but the incidence of MACE continued to be significantly lower in the Nebivolol group (9.9% vs. 15.8%, HR: 0.586, 95% CI: 0.421–0.815, P=0.002).
Conclusions: In STEMI patients with reduced LVEF treated with DESs, discharge prescription of Nebivolol was associated with a significantly lower incidence of MACE compared to Bisoprolol, while total death remained similar between the two groups after IPTW adjustment. These findings suggest that Nebivolol may offer additional benefits in reducing MACE in this population.
  • Park, Soohyung  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Choi, Cheol Ung  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Jeong, Myung Ho  ( Gwangju Veterans Hospital , Gwangju , Korea (the Republic of) )
  • Rha, Seung-woon  ( KOREA UNIV GURO HOSP , Seoul , Korea (the Republic of) )
  • Ahn, Woo Jin  ( National Medical Center , Seoul , Korea (the Republic of) )
  • Choi, Byoung Geol  ( Honam University , Gwangju , Korea (the Republic of) )
  • Choi, Se Yeon  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Byun, Jae Kyeong  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Lee, Youjin  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Chesario, Manda Satria  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Susanti, Melly  ( Korea University Guro Hospital , Seoul , Korea (the Republic of) )
  • Author Disclosures:
    Soohyung Park: No Answer | Cheol Ung Choi: No Answer | Myung ho Jeong: No Answer | Seung-Woon Rha: DO NOT have relevant financial relationships | Woo Jin Ahn: DO NOT have relevant financial relationships | Byoung Geol Choi: No Answer | Se Yeon Choi: DO NOT have relevant financial relationships | Jae Kyeong Byun: No Answer | Youjin Lee: No Answer | Manda Satria Chesario: DO NOT have relevant financial relationships | Melly Susanti: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Pharmacology and Coronary Revasc

Monday, 11/10/2025 , 10:45AM - 11:35AM

Moderated Digital Poster Session

More abstracts on this topic:
Clinical Responses to Aficamten Monotherapy Compared with Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis

Wang Andrew, Claggett Brian, Costabel Juan, Correia Edileide, Dybro Anne, Elliott Perry, Kulac Ian, Lakdawala Neal, Lewis Gregory, Mann Amy, Nair Ajith, Garcia-pavia Pablo, Poulsen Steen, Reant Patricia, Schulze Christian, Solomon Scott, Sohn Regina, Berhane Indrias, Heitner Stephen, Jacoby Daniel, Kupfer Stuart, Malik Fady, Masri Ahmad, Wohltman Amy, Fifer Michael, Maron Martin, Merkely Bela, Nassif Michael, Pena Pena Maria Luisa, Barriales-villa Roberto, Bilen Ozlem, Burroughs Melissa

Clinical Relevance of FFR-guided PCI According to Left Ventricular Systolic Function in Patients with Acute Myocardial Infarction and Multivessel Disease

Lee Yong-kyu, Hahn Joo-yong, Kim Hyun Kuk, Park Keun Ho, Choo Eun Ho, Kim Chan Joon, Ahn Gyun, Doh Joon-hyung, Lee Sang Yeub, Park Sang Don, Lee Hyun-jong, Lee Seung Hun, Kang Min Gyu, Nam Chang-wook, Choi Ki Hong, Park Taek Kyu, Yang Jeong Hoon, Song Young Bin, Choi Seung-hyuk, Kim Ju Han, Ahn Youngkeun, Jeong Myung Ho, Kim Hangyul, Gwon Hyeon-cheol, Koh Jin-sin, Hong Young Joon, Ahn Joon Ho, Cho Kyung Hoon, Kim Min Chul, Sim Doo Sun, Lee Joo Myung, Hong David

More abstracts from these authors:
Two-Year Clinical Outcomes of Patients with Critical Limb Ischemia versus Claudication in Femoropopliteal Artery Disease following Endovascular Therapy : An Analysis from K-VIS ELLA Registry

Rha Seung-woon, Park Chang Gyu, Oh Dong, Park Soohyung, Ahn Woo Jin, Cha Jinah, Hyun Sujin, Choi Se Yeon, Choi Byoung Geol, Sinurat Markz, Choi Cheol Ung

Clinical Implications of Elevated Lipoprotein(a) in the Absence of Significant Coronary Artery Stenosis

Ahn Woo Jin, Choi Cheol Ung, Rha Seung-woon, Choi Byoung Geol, Choi Se Yeon, Byun Jae Kyeong, Lee Youjin, Chesario Manda Satria, Susanti Melly, Park Soohyung

You have to be authorized to contact abstract author. Please, Login
Not Available